LifeNet Health

http://www.lifenethealth.org

The global standard in allograft surgical solutions.

LifeNet Health helps to save lives, restore health and give hope to thousands of patients each year. We are the world’s most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular therapies—a leader in the field of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process.

 Press Releases

• LifeNet Health’s ViviGen MIS optimizes leading cellular allograft for minimally invasive procedures (Sep 28, 2021)

  LifeNet Health, the world leader in allograft biologics, has optimized its industry-leading cellular bone matrix for minimally invasive surgery with the launch of ViviGen® MIS Delivery System, a major improvement in precision, efficiency and reliability over traditional bone-graft delivery.

  ViviGen MIS is the latest addition to the ViviGen family of cellular allografts, the first and only cellular biologics focused on recovering and protecting lineage-committed bone cells. The new delivery system offers a simple delivery method that is up to three-times faster than existing solutions like bone funnels.

  “ViviGen MIS brings graft delivery for minimally invasive procedures into the 21st Century,” said Rony Thomas, President and CEO of LifeNet Health. “It is a quantum leap forward that combines the clinical advantages of ViviGen with a fast, consistent delivery experience that eliminates one of the lingering challenges in MIS procedures. We are proud to bring this exciting solution to clinicians to support their patients’ healing.”

  The ViviGen MIS system includes two single-use components: a pre-filled cannula containing the graft material and an easy-to-use delivery device. The convenience of a pre-filled cannula removes the difficulty and inconsistency associated with other bone graft-delivery options. The system facilitates rapid thawing of the graft, and it takes mere seconds to attach a cannula to the delivery device. ViviGen MIS is indicated for spine and orthopedic procedures requiring a bone graft.

  Since its launch in 2014, ViviGen has grown into the world’s leading cellular allograft, having been implanted in nearly 200,000 patients. It is comprised of cryopreserved, cortical cancellous bone matrix containing viable bone cells and demineralized bone to provide the three critical elements for bone healing — osteoconductivity, osteoinductivity and osteogenecity — that make ViviGen a viable alternative to autograft.

  A growing body of published data illustrates the clinical advantages of ViviGen. Studies have shown that it supports fusion rates as high as 98 percent even in complex, multi-level fusions while also being associated with significantly lower hospital charges than other grafting solutions. Learn more at www.lifenethealth.org/vivigen.

  About LifeNet Health

  LifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world's most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to www.lifenethealth.org.

• LifeNet Health features biologics that transform care and improve healing at 2021 NASS Annual Meeting (Sep 29, 2021)

  LifeNet Health is highlighting its advanced solutions for fusion during the North American Spine Society (NASS) 2021 Annual Meeting in Boston Sept. 29-Oct. 1 (Booth #2719). The global leader in allograft biologics is featuring innovations that include the world’s most versatile osteobiologic, PliaFX^® Prime; the clinically proven portfolio of VertiGraft^® structural allografts; and the new, first-of-its-kind ViviGen^® MIS Delivery System that optimizes the proven power of lineage-committed bone cells for minimally invasive surgery (MIS) procedures. 

  NASS attendees can experience these unique solutions live at LifeNet Health’s exhibit or visit its online showcase to see more about how they support cost-effective care and exceptional patient outcomes.

  “LifeNet Health’s technologies are designed to deliver better biologics that support healing,” said Daniel Osborne, Vice President of Global Marketing and Commercial Strategy. “We look forward to sharing with clinicians at NASS how these solutions can bring unsurpassed effectiveness to their patients and unrivaled efficiency to their procedures.”

  In addition, visitors to LifeNet Health’s exhibit have the exclusive opportunity to try the ViviGen MIS delivery device. This new system brings the clinical advantages of ViviGen into a format specifically designed to make graft delivery faster, more predictable, and more precise in MIS procedures.

  Backed by Data

  NASS participants can explore peer-reviewed publications with compelling data about the clinical effectiveness of LifeNet Health’s solutions. This includes published data showing that patients who received VertiGraft implants experienced significantly lower rates of pseudoarthrosis and reoperation than patients who received PEEK implants, as well as data that demonstrates how ViviGen supports successful outcomes even in complex, multi-level fusions and in patients with comorbidities known to hinder bone healing.

  Delivering Extraordinary Value

  Throughout the exhibition, LifeNet Health also will highlight the unique combination of efficacy and economic value found in biologics such as PliaFX Prime and ViviGen. With no carrier to dilute its bone-healing potential, PliaFX Prime’s all-cortical-fiber design is driven by data showing that 100 percent-bone grafts grow more bone than those with a carrier.^1,2 That also means PliaFX Prime delivers 100 percent value by providing more bone by volume than grafts that rely on a carrier to improve handling.

  Similarly, ViviGen Cellular Bone Matrix has been shown to deliver not only exceptional clinical outcomes — with complex, multi-level fusion rates as high as 98 percent — but also significantly lower hospital charges than other grafting solutions. A 2019 study showed that charges associated with ViviGen were as much as $50,000 lower than those associated with a leading growth factor-based bone graft substitute.

  Learn more about LifeNet Health portfolio of biologics for fusion and the data supporting them at www.lifenethealthorg/NASS2021. 

  About LifeNet Health
  LifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world's most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to www.lifenethealth.org.

  1. Boyan BD, Ranly DM, McMillan J, et al. Osteoinductive Ability of Human Allograft Formulations. J Periodontol. September 2006.
  2. Data on file LifeNet Health TR-0446.